BIOTRONIK, a leading German medical technology company specializing in cardiovascular devices, has opened a new Asia-Pacific Manufacturing and Research Hub in Singapore. The 20,000-square-metre facility, located at BIOHUB in Kallang, will serve as the company’s central hub for the Asia-Pacific region, employing hundreds of staff across manufacturing, quality assurance, and research and development functions. This expansion highlights BIOTRONIK’s commitment to strengthening its presence and capabilities in the fast-growing Asia-Pacific market.
The Singapore hub will focus on the development and production of advanced cardiovascular medical devices, including pacemakers, implantable defibrillators, cardiac resynchronization therapy systems, and vascular intervention technologies. By integrating both manufacturing and R&D at one site, BIOTRONIK aims to accelerate innovation, streamline product development, and better address the specific healthcare needs of patients in the region.
Singapore was selected for its strong biomedical ecosystem, skilled talent pool, and strategic regional connectivity, making it an ideal base for BIOTRONIK’s Asia-Pacific operations. The new hub is expected to enhance supply chain resilience, enable faster delivery of products, and foster closer collaboration with local healthcare providers and research partners.
This significant investment signifies BIOTRONIK’s long-term commitment to the Asia-Pacific region and its mission to deliver high-quality, innovative cardiovascular solutions to patients worldwide. The new Singapore facility positions the company to play a leading role in advancing cardiac care and medical technology across Asia-Pacific in the coming years.
(Source: Biotronik)
